UW-Madison biomanufacturer offers essential gene-transfer capacity

Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the Waisman lab’s growing importance in the biopharma business, as it’s the only facility on campus meeting FDA “good manufacturing practices” rules for large-scale manufacturing of biological therapies.

A decade after stem cell feat, research ramps up

A decade after scientists announced the development of induced pluripotent stem cells, Waisman investigators, including Su-Chun Zhang and David Gamm, continue to use these cells to research and develop potential therapies for several disorders and conditions, such as ALS, Parkinson’s disease, spinal cord injury, and macular degeneration.

Waisman Biomanufacturing to be part of UW-Madison partnership in $20 million cell-based therapy center

Waisman Biomanufacturing and Waisman affiliate investigators Randolph Ashton and Krishanu Saha will be part of a new engineering research center that will develop transformative tools and technologies for the consistent, scalable and low-cost production of …